Gesundheit
Straumann sales growth driven by strong demand in the Asia-Pacific region
Swiss dental implant maker Straumann on Tuesday reported double-digit percentage growth in organic revenue for the third quarter as more people seek dental services globally,
Novartis improves its 2024 outlook for the third time with Cosentyx
Swiss drugmaker Novartis on Tuesday raised its 2024 profit forecast for the third time amid greater use of its prescription drugs such as psoriasis and
India’s Sun Pharma beats second-quarter profit expectations
Sun Pharmaceuticals, India’s largest drugmaker by revenue, reported second-quarter profit above analysts’ estimates, helped by higher demand for its speciality drugs used to treat rare
Sanofi’s profit growth beats market expectations thanks to early start of vaccine sales
French drugmaker Sanofi posted stronger third-quarter profit growth than analysts expected, helped by an earlier-than-expected start to the vaccination season. The company’s quarterly operating income,
Pfizer executives seek to demonstrate change as Starboard approaches
Pfizer’s quarterly financial report released on Tuesday coincided with a critical moment for the US drugmaker and its CEO, as activist hedge fund Starboard Value
Sanofi’s profit growth beats market expectations thanks to early start of vaccine sales
French drugmaker Sanofi on Friday posted stronger third-quarter profit growth than analysts expected, helped by an earlier-than-expected start to the vaccination season.
The US FDA reports that the number of E. coli infections linked to McDonald’s has risen to 75
The number of people infected by an E. coli outbreak linked to McDonald’s the U.S. Food and Drug Administration said Friday that the number of
US FDA approves Iterum for the treatment of urinary infection
The US Food and Drug Administration has approved Iterum Therapeutics The health regulator on Friday said the oral antibiotic is intended to treat certain types
Pfizer brings Vanguard veteran to board amid Starboard struggles
On Tuesday, Pfizer appointed the former CEO of Vanguard, the pharmaceutical giant’s biggest investor, to its board as it faced pressure from activist hedge fund
J&J must pay $15 million to a man who claims talcum powder caused his cancer
Johnson & Johnson jurors ruled Tuesday that the company must pay $15 million to a Connecticut resident who claims he developed mesothelioma, a rare form